Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15260687 | 1.00 | APLNR (0.32) | APLNRCES2CES1 | |
| SCHEMBL15260635 | 0.78 | AOC3 (0.38) | — | |
| SCHEMBL15260634 | 0.78 | AOC3 (0.38) | — | |
| SCHEMBL719092 | 0.77 | CYP24A1 (0.35) | — | |
| SCHEMBL15229196 | 0.75 | SLC6A2 (0.35) | APLNR | |
| SCHEMBL15229326 | 0.75 | SLC6A2 (0.35) | APLNR | |
| SCHEMBL15229330 | 0.74 | SLC6A4 (0.34) | APLNR | |
| SCHEMBL31022566 | 0.74 | SLC6A4 (0.34) | APLNR | |
| SCHEMBL15229215 | 0.74 | SLC6A4 (0.34) | APLNR | |
| SCHEMBL22264312 | 0.73 | APLNR (0.34) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321262-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-106349217-B | Serine/threonine kinase inhibitors | 阵列生物制药公司 | 2020-08-28 | — | — | CN | disclosed |
| EP-3321262-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20180127393-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-05-10 | — | — | US | disclosed |
| US-9708290-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160122316-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-9259470-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20140249127-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-8697715-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20130252934-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122316-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | APLNR 4272/4885CES2 4305/4885CES1 2744/4885 |
| US-20140249127-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | APLNR 4272/4885CES2 4305/4885CES1 2744/4885 |
| US-20180127393-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | APLNR 4272/4885CES2 4305/4885CES1 2744/4885 |
| US-20130252934-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | APLNR 4272/4885CES2 4305/4885CES1 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.